Cargando…

Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization

BACKGROUND: Adults with comorbid illness are known to be at excess risk of IPD. We evaluated the burden of IPD in adults, with and without comorbidity, during the period before and after introduction of PCV13 in children and selected adults. METHODS: We employed a retrospective cohort design and dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelton, Stephen I, Bornheimer, Rebecca, Shea, Kimberly M, Sato, Reiko, Weycker, Derek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630750/ http://dx.doi.org/10.1093/ofid/ofx163.1195

Ejemplares similares

Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization
por: Pelton, Stephen I, et al.
Publicado: (2019)

Pneumonia in young adults with asthma: impact on subsequent asthma exacerbations
por: Pelton, Stephen I, et al.
Publicado: (2019)

Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease
por: Bornheimer, Rebecca, et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions
por: Shea, Kimberly M., et al.
Publicado: (2014)

Rethinking Risk for Pneumococcal Disease in Adults: The Role of Risk Stacking
por: Pelton, Stephen I., et al.
Publicado: (2015)

597 Increase in IPD incidence in Adults in 2013-2014 after 2 consecutive years of decline following introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
por: Baxter, Roger, et al.
Publicado: (2014)

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
por: Marbaix, Sophie, et al.
Publicado: (2018)

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
por: Lapidot, Rotem, et al.
Publicado: (2020)

Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.
por: Pilishvili, Tamara, et al.
Publicado: (2017)

HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV)
por: Meiring, Susan, et al.
Publicado: (2016)

1475. Impact of a Routine Infant PCV Program on the Serotype Distribution of Episodes of Invasive Pneumococcal Disease (IPD) and Non-bacteremic Pneumococcal Pneumonia in Adults
por: McGeer, Allison
Publicado: (2020)

1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
por: Pilishvili, Tamara, et al.
Publicado: (2020)

Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
por: Lapidot, Rotem, et al.
Publicado: (2017)

Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
por: van der Linden, Mark, et al.
Publicado: (2015)

Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions
por: Weycker, Derek, et al.
Publicado: (2016)

1888. A Nationwide Outbreak of Invasive Pneumococcal Disease (IPD) Caused by a Novel Streptococcus Pneumoniae Serotype 2 (SP2) Clone in the PCV13 Era, in Israel
por: Dagan, Ron, et al.
Publicado: (2019)

176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children’s Hospitals in the United States. 2014–2019
por: Kaplan, Sheldon L, et al.
Publicado: (2020)

Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain
por: Càmara, Jordi, et al.
Publicado: (2017)

Stability of the pneumococcal population structure in Massachusetts as PCV13 was introduced
por: Chang, Qiuzhi, et al.
Publicado: (2015)

Initial Effects of the National PCV7 Childhood Immunization Program on Adult Invasive Pneumococcal Disease in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2014)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

1149. Contribution of S.pneumoniae Serotypes in Adults with Invasive Pneumococcal Disease (IPD) and Pneumococcal Community-acquired Pneumonia (pCAP)
por: Apodaca, Kevin, et al.
Publicado: (2023)

Pneumococcal serotypes in children, clinical presentation and antimicrobial susceptibility in the PCV13 era
por: Izquierdo, C., et al.
Publicado: (2020)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012–2018
por: Savrasova, Larisa, et al.
Publicado: (2021)

Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13
por: Mitchell, Patrick K., et al.
Publicado: (2019)

Invasive Pneumococcal Disease (IPD) Serotype Frequency in Iranian Patients
por: Mehrabi Tavana, Ali, et al.
Publicado: (2013)

Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study
por: Lo, Stephanie W, et al.
Publicado: (2019)

Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults
por: Humphreys, Hilary, et al.
Publicado: (2023)

Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs
por: Horn, Matthias, et al.
Publicado: (2023)

2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
por: McGeer, Allison, et al.
Publicado: (2019)

Rates of pneumonia among children and adults with chronic medical conditions in Germany
por: Pelton, Stephen I., et al.
Publicado: (2015)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
por: Vila-Córcoles, Angel, et al.
Publicado: (2023)

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
por: Galanis, Ilias, et al.
Publicado: (2016)

Identifying an appropriate PCV for use in Senegal, recent insights concerning Streptococcus pneumoniaeNP carriage and IPD in Dakar
por: Ba, Fatim, et al.
Publicado: (2014)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

Pediatric Invasive Pneumococcal Disease (IPD) in Yogyakarta, Indonesia: A Case Series
por: Arguni, Eggi, et al.
Publicado: (2022)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hoj6r8afir8i7i4iohsm0ksts4